Dupilumab for pruritus associated with dystrophic epidermolysis bullosa: A systematic review

Key Points

• This review aims to assess the effectiveness of dupilumab in alleviating pruritus associated with dystrophic epidermolysis bullosa.
• Conducted a systematic review of available studies on dupilumab for pruritus.
• Data sources included clinical trials and case reports on dystrophic epidermolysis bullosa.
• Dupilumab showed promising results in reducing pruritus in patients with dystrophic epidermolysis bullosa.
• Increased patient-reported outcomes related to itch relief were noted.